Table of Contents
CHAPTER ONE: EXECUTIVE SUMMARY
- Epidemiology
- Management of Schizophrenia
- Drugs in Development
- Market Summary
- World Market for Novel Antipsychotics
- Scope and Methodology
CHAPTER TWO: INTRODUCTION
- Schizophrenia
- Symptoms
- Economic Burden
- Causes
- Complications
- Distorted Perceptions of Reality
- Hallucinations and Illusions
- Delusions
- Incidence
- Types
CHAPTER THREE: TREATMENT OPTIONS
- Pharmacological Treatments
- Relapse Management
- Adherence
- Non-Pharmacological Treatments
CHAPTER FOUR: DRUGS IN CLINICAL TRIALS
- Newer Treatment Approaches
- Preclinical Agents
- A320436
- Dopamine D2 Partial Agonist Agent
- ORG 25543
- MEM 3454
- Clera 120
- Phase I Clinical Agents
- LY 483518
- SB 277011
- MGS 0028
- Muscarinic M1 Agonist Compound
- SGS 518
- Neboglamine
- Phase II Clinical Agents
- DAR 0100
- Palindore
- Reminertant
- Lurasidone
- Talnetant
- Phase III Clinical Agents
- Bifeprunox
- Lonasen
- Iloperidone
CHAPTER FIVE: MARKET FORECASTS
- Opportunities and Drivers
- World Market Breakdown
- 5H2 and D2 Antagonist Antipsychotic Agents
- Atypical Antipsychotic Agents
- 5H1A and D2 Partial Agonist and D2 and D3 Antagonist Agents
- Novel Antipsychotic Agents
- Geographical Breakdown of Antipsychotic Agents
CHAPTER SIX: KEY PLAYERS
- Astra Zeneca PLC
- Abbott Laboratories
- Johnson and Johnson
- Novartis AG
- Pfizer Inc.
LIST OF EXHIBITS
- Exhibit 1: Schizophrenia Cases, Geographical Breakdown
- Exhibit 2: Status of Key Late-Stage Antipsychotic Agents
- Exhibit 3: World Market for Antipsychotics Summary 2004-2009
- Exhibit 4: World Market for Antipsychotics by Geographic Segment Summary 2004-2009
- Exhibit 5: World Market for Antipsychotics by Drug Type Summary 2004-2009
- Exhibit 6: World Market for Novel Antipsychotics 2006-2009
- Exhibit 7: Schizophrenia Cases, Geographical Breakdown
- Exhibit 8: World Market for Antipsychotic Agents 2004-2009
- Exhibit 9: Expected Launch Dates of Late Stage Antipsychotic Agents
- Exhibit 10: World Market for Antipsychotics by Drug Type (5 H2 & D2 antagonists, atypical
antipsychotics, 5 H1A & D2 partial agonist, D2 & D3 antagonists, and benzamides) 2004-2009
- Exhibit 11: World Market for 5H2 and D2 Antagonist Segment
- Exhibit 12: World Market for Atypical Antipsychotic Segment
- Exhibit 13: World Market for 5H1A and D2 Partial Agonist Segment
- Exhibit 14: World Market for D2 and D3 Antagonist Segment
- Exhibit 15: World Market for Novel Antipsychotic Therapies 2006-2009
- Exhibit 16: World Market for Antipsychotics by Geographic Segment (U.S., Europe, Japan, ROW)
2004-2009
| 
View Cart
